Security key
68062P106
Olema Pharmaceuticals, Inc. - Common Stock (OLMA)
CUSIP: 68062P106
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 101,411,965
- Total 13F value
- $1,511,791,720
- Share change
- +9,862,300
- Put/Call ratio
- 24%
- SEC-reported price per share
- $14.91
- Number of holders
- 193
- Value change
- +$99,306,003
- Number of buys
- 110
- Number of sells
- 98
- Shares outstanding
- 87,946,648
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
193
Top holders
10
OLMA full security history
Ownership snapshot
Full 13F holder table
Olema Pharmaceuticals, Inc. SEC filings
Olema Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of OLMA - Olema Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 12%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
12%
Paradigm Biocapital Advisors LP
10%
Janus Henderson Group Ltd.
8.2%
Bain Capital Life Sciences Opport...
8.2%
Invus Global Management, LLC
5.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
12%
|
$250,051,474
9,998,060 shares
|
+$124,423,925 | 27 Feb 2026 |
| Paradigm Biocapital Advisors LP |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
10%
from 13D/G
|
$188,604,300
7,544,172 shares
|
— | 31 Dec 2025 |
| Janus Henderson Group Ltd. |
13F
13D/G
Company · JANUS HENDERSON GROUP PLC
|
8.2%
from 13D/G
|
$167,901,108
6,710,194 shares
|
— | 31 Dec 2025 |
| Bain Capital Life Sciences Opportunities IV, L.P. |
13D/G
|
8.2%
|
$111,425,979
7,473,238 shares
|
-$15,437,859 | 31 Mar 2026 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
5.1%
|
$108,693,078
4,461,949 shares
|
$0 | 16 Mar 2026 |
| Logos Global Management LP |
13F
13D/G
Company
|
4.7%
from 13D/G
|
$80,221,875
3,208,875 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
193
Shares
101,411,965
Rows available
193
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
193
Q1 2026 holders
193
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|